http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2394564-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a6907c0df7c11e72803b375909e45fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9494c30f8f6cb9e15dc21e0d6895855 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 |
| filingDate | 2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3f0bff1c920c3eaf780643495ef04de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fba409fd58742cc3f13f55ce548eba1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2395b85fd481b1e436fe87495a82cb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ffef836579578b50a5fb4d436cdaa63 |
| publicationDate | 2010-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2394564-C1 |
| titleOfInvention | Method of optimising functional reactivity of cardio-vascular system in case of crisis course of arterial hypertension with disturbance of glucose tolerance |
| abstract | FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardiology, and deals with normalisation of functional reactivity of cardio-vascular system (CVS) in case of crisis course of arterial hypertension with disturbance of glucose tolerance. For this purpose estimation of CVS functional reactivity state under psychoemotional load is carried out by registration of systolic diastolic everage dynamic pressure (APav.dyn.) and heart rate (HR). On the basis of obtained data functional reactivity index (FRI) is determined before and after load, using the formula: FRI= APav.dyn.x HR)100 (conv. units). If FRI value after load increases on more than 20 conv.units, treatment including irbersartan 150 mg in the morning 1 time and lacidipine 4 mg in the morning 1 time during not less than 2 months. ^ EFFECT: such complex of medicamentary therapy in combination with empirically selected treatment duration ensures normalisation of CVS functional reactivity in said group of patients due to potentiation of therapeutic effect of applied medications. ^ 1 ex |
| priorityDate | 2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.